BioSpace News Archive

Precision Biologics will deliver a poster presentation on preliminary results of the ongoing phase 2 trial, combining NEO-201 with pembrolizumab for the treatment of patients resistant to prior checkpoint inhibitor therapy at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting at the San Diego Convention Center in San Diego, CA on November 3rd, 2023.

Gedeon Richter Plc. together with Sumitomo Pharma America, Inc. and Sumitomo Pharma Switzerland, GmbH announce that the European Commission has granted approval of a Type II Variation application for RYEQO® for the symptomatic treatment of endometriosis in women with a history of previous medical or surgical treatment for their endometriosis.

Electra Therapeutics, Inc announced today that the company will present the initial clinical data for its lead drug candidate, ELA026, in a poster at the American Society of Hematology (ASH) annual meeting being held in San Diego, California, December 9-12, 2023.

MorphoSys AG announced that data from the Phase 3 MANIFEST-2 trial of pelabresib, an investigational BET inhibitor, in combination with the JAK inhibitor ruxolitinib in JAK inhibitor-naïve patients with myelofibrosis will be presented during an oral presentation on Sunday, December 10, at the 65th American Society of Hematology Annual Meeting and Exposition.

Mineralys Therapeutics, Inc. presented a new post-hoc analysis from the Target-HTN Phase 2 trial of lorundrostat, a highly selective aldosterone synthase inhibitor, in individuals with uncontrolled hypertension and resistant hypertension.

Insightec announced that the editorial panel of the American Medical Association approved their application to establish a new Category I Current Procedural Terminology code to facilitate reimbursement for MR-guided focused ultrasound ablation of neurological targets.

Bayer and the Broad Institute of MIT and Harvard have renewed their research alliance, adding five years to a 10-year collaboration that has already yielded three clinical oncology candidates.

PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation announced that new abstracts on ropeginterferon alfa-2b-njft will be presented during the 15th International Congress on Myeloproliferative Neoplasms in Brooklyn, NY on November 2-3, 2023, and during the 65th American Society of Hematology Annual Meeting in San Diego, CA on December 9-12, 2023.

Biostax Corp, a hub and spoke biotech development engine, announces the appointment of Ms. Clay Caperton to its Board of Directors.

The Multiple Myeloma Research Foundation announced the recipients of three $7 million MMRF Myeloma Accelerator Challenge Program Grants totaling $21 million.